Xcell Biosciences Announces Collaboration with ElevateBio to Advance Technology Development for Cell and Gene Therapies
Excerpt from the Press Release:
SAN FRANCISCO–(BUSINESS WIRE)–Xcell Biosciences, Inc. (Xcellbio), a platform technology company focused on cell and gene therapy applications, today announced a collaboration with ElevateBio, LLC (ElevateBio), through which the companies aim to explore novel approaches to improving therapeutic potency of cell and gene therapies. As part of this collaboration, ElevateBio becomes the first member of Xcellbio’s beta program for its new AVATAR Foundry™ device. In addition, Michael Paglia, Chief Technology Officer at ElevateBio’s BaseCamp®, has joined Xcellbio’s Scientific Advisory Board.
ElevateBio is a technology-driven company commercializing its enabling technologies, manufacturing capabilities, and industry-leading expertise through partnerships to accelerate the development of genetic medicines. The company’s integrated ecosystem combines its BaseCamp process development and current Good Manufacturing Practice (cGMP) manufacturing business with its technology stack that includes gene editing, cell engineering technologies, and viral and non-viral delivery.
“At BaseCamp, we work with industry partners to design the best process for their product and recognize the importance of emerging technologies that will revolutionize how cell and gene therapies are manufactured,” said Mr. Paglia. “I am excited to join the Xcellbio advisory board and look forward to joining Brian and the team on the collaboration with BaseCamp.”
Click the button below to read the entire Press Release:
Discover What Sets TrialStat Apart From Ordinary EDC Platforms
Click the image or button below to explore our eClinical Suite Platform and discover what sets TrialStat apart from competing EDC platforms.
Request Your Demo Today!
From rapid database build through database lock, we deliver consistent quality on-time and on-budget. Ready to upgrade your eClinical toolkit?